Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands

Christel J M de Blok,1,2 Chantal M Wiegjes,1,2 Nienke MNota,1,2 Klaartje van Engelen,3
Muriel A Adank,4 Koen M A Dreijerink,1,2 Ellis Barbé,5 Inge R H M Konings,6 Martin den Heijer1,2

ABSTRACT
OBJECTIVE
To investigate the incidence and characteristics of breast cancer in transgender people in the Netherlands compared with the general Dutch population.

DESIGN
Retrospective, nationwide cohort study.

PARTICIPANTS
2260 adult trans women (male sex assigned at birth, female gender identity) and 1229 adult trans men (female sex assigned at birth, male gender identity) who received gender affirming hormone treatment.

MAIN OUTCOME MEASURES
Incidence and characteristics (eg, histology, hormone receptor status) of breast cancer in transgender people.

RESULTS
The total person time in this cohort was 33 991 years for trans women and 14 883 years for trans men. In the 2260 trans women in the cohort, 15 cases of invasive breast cancer were identified (median duration of hormone treatment 18 years, range 7–37 years). This was 46-fold higher than in cisgender men (standardised incidence ratio 46.7, 95% confidence interval 27.2 to 75.4) but lower than in cisgender women (standardised incidence ratio 0.1 to 0.5).

CONCLUSIONS
This study showed an increased risk of breast cancer in trans women compared with cisgender men and a lower risk in trans men compared with cisgender women. In trans women, the risk of breast cancer increased during a relatively short duration of hormone treatment and the characteristics of the breast cancer resembled a more female pattern. These results suggest that breast cancer screening guidelines for cisgender people are sufficient for transgender people using hormone treatment.

Introduction
Breast cancer is the most common malignancy in females,1 but it is rare in males. The lifetime risk in the general female population is 12% and in the general male population is 0.1%.2 Several risk factors have been identified for breast cancer, including advancing age, genetics (eg, BReast CAncer 1/2 mutations (BRCA1/2)), family history, overweight or obesity, breast density, tobacco use, alcohol use, and null parity in females.3 4 The molecular pathogenesis of breast cancer differs between sexes.5 For instance, cancers positive for human epidermal growth factor receptor 2 (HER2) are rare in males (1.7%), whereas 6–12% of the breast cancers in females express HER2.5 7

Transgender people experience an incongruence between the sex assigned to them at birth and their experienced or expressed gender. In the Netherlands, the number of referrals for psychological counselling, for endocrine or surgical treatment, or a combination of those has been seen over the past 10 years.8 As for body hair and body composition,9 10 Transgender people experience an incongruence between the sex assigned to them at birth and their experienced or expressed gender. In the Netherlands, an estimated one in 2800 birth assigned males and one in 5200 birth assigned females identify themselves as transgender.9 However, a substantial increase in the number of referrals for psychological counselling, for endocrine or surgical treatment, or a combination of those has been seen over the past 10 years.8

Transgender people can receive gender affirming hormones (sex steroids) to reduce psychological distress and to induce desired physical changes, such as for body hair and body composition.9 10 In trans women (male sex assigned at birth, female gender identity), treatment usually consists of antiandrogens and oestrogens. In trans men (female sex assigned at birth, male gender identity), treatment usually consists of testosterone. Besides gender affirming hormone treatment, transgender people might also want surgical transition, which can consist of breast augmentation.

What is already known on this topic
Transgender people, defined as an incongruence between sex assigned at birth and experienced gender, can receive gender affirming hormone treatment (sex steroids) to induce desired physical changes. Whether (exogenous) sex steroids influence breast cancer risk and pathogenesis in transgender people is not fully understood. Currently, information about the risk of breast cancer in transgender people is limited.

What this study adds
An increased risk of breast cancer was observed in trans women (male sex assigned at birth, female gender identity) compared with cisgender men and a lower risk in trans men (female sex assigned at birth, male gender identity) compared with cisgender women. A striking finding was that in trans women the risk of breast cancer increased in a relatively short time. The absolute risk of breast cancer in transgender people remains low, and therefore following breast cancer screening guidelines for cisgender people seems sufficient for transgender people using hormone treatment.
and orchiectomy or vaginoplasty in trans women and subcutaneous mastectomy and uterus extirpation or oophorectomy, or both, and phalloplasty in trans men. Subcutaneous mastectomy in trans men is often subtotal to obtain an aesthetic masculine thorax.

Whether (exogenous) sex steroids influence breast cancer risk and pathogenesis in transgender people is not fully understood. It is known that sex steroids induce changes in breast tissue. During female puberty and in trans women receiving hormone treatment, mammary development includes duct and lobule formation and an increase in deposition of fat in the breasts. Some structural changes occur in breast tissue under the influence of testosterone, such as an increase in fibrous tissue and the up regulation of potential oncogenes. Large prospective studies have shown that hormone replacement therapy increases the risk of breast cancer in cisgender postmenopausal women, in particular in those using both oestrogens and progestogens, which could suggest an increased breast cancer risk in trans women receiving hormone treatment compared with cisgender men.

Currently, information about the risk of breast cancer in transgender people is limited. To date, 22 cases of breast cancer in trans women and 20 cases in trans men have been published. However, reliable estimations of the risk in transgender people are lacking because of the heterogeneity in the population and study cohorts.

To gain more insight into the risk of breast cancer in transgender people receiving hormone treatment and the influence of (exogenous) sex steroids on the development of breast cancer, we investigated the incidence and characteristics of breast cancer in a well documented cohort of transgender people receiving hormone treatment in the Netherlands, compared with the general Dutch population.

Methods
Study population
For this retrospective cohort study, we identified all transgender people who visited the gender clinic of the VU University Medical Centre Amsterdam between 1972 and January 2016 for either psychological, endocrine, or surgical treatment. More than 95% of transgender people in the Netherlands receive healthcare at our centre. People were excluded from analyses if they never used hormone treatment or the start date was unknown, they were younger than 18 years at the time of the study, or they used alternating oestrogen and testosterone during the follow-up time because of regret about their transition. As data on breast cancer diagnosis were retrieved from the Nationwide Network and Registry of Histopathology and Cytopathology in the Netherlands (PALGA), which covers all pathology diagnoses since 1991, we also excluded those whose last visit to our gender identity clinic was before 1991.

Most trans women were treated with a combination of antiandrogens and oestrogens. Antiandrogen treatment usually consisted of cyproterone acetate (a progestogenic antiandrogen, 10 to 100 mg daily) or spironolactone (100 to 200 mg daily), and treatment was often stopped after orchiectomy. Oestrogen was prescribed as ethinylestradiol (25 to 100 µg daily), conjugated oestrogens (0.625 to 1.25 mg daily), estradiol patches (50 to 150 µg/24 hours twice weekly), estradiol implants (20 mg every 3 to 6 months), estradiol injections (10 to 100 mg every 2 to 4 weeks), estradiol valerate (2 to 6 mg daily), or estradiol gel (0.75 to 3.0 mg daily). In recent years, mainly estradiol valerate, estradiol patches, or estradiol gel have been used. Trans men were treated with either testosterone gel (20 to 100 mg daily), intramuscular testosterone esters (150 to 250 mg every 2 to 3 weeks), or oral or intramuscular testosterone undecanoate (orally: 40 to 160 mg daily, intramuscularly: 1000 mg every 10 to 14 weeks). Trans men who experienced persistent menstrual blood loss during testosterone treatment were in some cases treated with additional progestogens such as lynestrenol (5 to 10 mg daily).

People who started hormone treatment younger than 18 years often received only gonadotrophin releasing hormone agonists before the addition of oestrogen or testosterone treatment.

Data collection
After inclusion of eligible people, we collected data about age at start of hormone treatment, type of treatment, gender affirming surgery, and medical history. Subsequently, the data were linked to PALGA and Statistics Netherlands (CBS). We retrieved data on year of breast cancer diagnosis and breast cancer histology from PALGA. To adequately calculate the follow-up time, we retrieved data on mortality from Statistics Netherlands.

Statistical analysis
Data from trans women and trans men were analysed separately. Baseline data are presented as means with standard deviations for normally distributed data, and medians with interquartile ranges, ranges, or both for non-normally distributed data. For those people who had started hormone treatment before treatment at our clinic, we used the first known start date of the treatment to calculate the most accurate duration. To calculate standardised incidence ratios, we determined the number of observed breast cancer cases in this cohort. Person time was calculated as the number of years from the first known start date of hormone treatment to the first terminating event: breast cancer diagnosis, death, or end of study period (31 August 2017). The number of expected cases were calculated using age matched incidence rates for cisgender men and women from the Netherlands Comprehensive Cancer Organisation (IKSU). We calculated the number of expected cases for the whole study population and for the age categories younger than 30 years, 30 to 50 years, and older than 50 years. Finally, standardised incidence ratios with 95% confidence intervals were calculated with a mid-P exact test. Mean oestradiol and testosterone concentrations for each participant.
were calculated by averaging the results from the measurements performed during hormone treatment. Analyses were carried out using STATA statistical software, version 14.1 (Statacorp, College Station, TX) and OpenEpi version 3.01 (www.OpenEpi.com).

Patient and public involvement
Owing to the design of this study, there was no patient or public involvement. The results of this paper will be shared with the public through our institutions’ website and during an open science evening at our centre, which is intended for transgender people, their friends and family, and other interested people.

Results
Of 6793 transgender people identified, 4432 were birth assigned males and 2361 were birth assigned females. After exclusions, 2260 trans women and 1229 trans men were included in this study (fig 1). The median age at start of hormone treatment in trans women was 31 years (interquartile range 23-41 years) and in trans men was 23 (interquartile range 19-31) years. The median person time in trans women was 13 (interquartile range 5-23, range 0-63) years and in trans men was 8 years (interquartile range 3-20, range 0-47) years. The total person time was 33991 years and 14883 years, respectively. Table 1 shows the baseline characteristics of the study cohort.

In 17 of the 2260 trans women, a total of 18 cases of breast cancer (15 invasive and three non-invasive) were diagnosed after a median 18 (interquartile range 12-27, range 7-37) years of hormone treatment. The median age at diagnosis was 50 (interquartile range 43-55) years. The breast cancers were mostly tumours of ductal origin (67%, n=10/15). The oestrogen receptor was positive in 83% (n=10/12) of the tumours, the progesterone receptor was positive in 67% (n=8/12), and HER2 was positive in 8% (n=1/12). In trans women with breast cancer the median oestradiol level was 116 pmol/L (range 60-191 pmol/L), comparable with the median level in the whole cohort of trans men. The mean testosterone level in trans men with breast cancer was lower than the median level in the whole cohort (13.2 nmol/L (range 12.8-16.0 nmol/L) v 23.3 (15.9-35.2) nmol/L, respectively). With an overall standardised incidence ratio of 0.2 (95% confidence interval 0.1 to 0.5) in trans men, the risk of breast cancer was lower than in Dutch cisgender men. This suggests that hormone treatment alters the risk of breast cancer in transgender people compared with initial risk based on their birth assigned sex. The median age at breast cancer diagnosis was 52 years in trans women and 46 years in trans men, both lower than the average age of 61 years in Dutch cisgender women. HER2 receptor status in trans women was higher than expected in male breast cancer.

Comparison with other studies
The overall incidence of breast cancer for trans women in the Netherlands compared with Dutch cisgender men. In both trans women and trans men, the risk of breast cancer was lower than in Dutch cisgender women. This suggests that hormone treatment alters the risk of breast cancer in transgender people compared with initial risk based on their birth assigned sex. The median age at breast cancer diagnosis was 52 years in trans women and 46 years in trans men, both lower than the average age of 61 years in Dutch cisgender women. HER2 receptor status in trans women was higher than expected in male breast cancer.

Fig 1 | Study flowchart

![Fig 1](image_url)
is in line with our results. In the other study, the breast cancer risk could have been underestimated because of technical limitations resulting in overestimation of the total follow-up time and not including people who underwent treatment for breast cancer in other hospitals. We addressed these limitations in our study. None of the reported cases in this study have been previously published.

In accordance with previous studies, we observed a younger age at time of breast cancer diagnosis in transgender people compared with cisgender women. Moreover, the exposure to hormone treatment before breast cancer diagnosis was relative short in trans women, at a median of 18 years, suggesting a rapid development of breast tumours in a subset of people. This observation could be explained by genetic susceptibility. Genetics data were available for one trans woman who is a carrier of a BRCA 1 germ line mutation. Another explanation might be the presence of undiagnosed hormone sensitive cancer before treatment, which could become apparent when stimulated by hormones. In trans women, most breast tumours were of the luminal type, suggesting that the tumours are driven in a cell autonomous fashion by the growth stimulatory actions of oestrogens as well as the progestogenic characteristics of the predominantly used antiandrogen cyproterone acetate. As androgens are known to inhibit the progression of luminal breast cancer, antiandrogen treatment and orchietomy might have contributed to tumour initiation in the affected people.

Breast cancer screening advise
Current recommendations suggest that trans women and trans men who have not undergone mastectomy should be biennially screened with mammography from the age of 50 years and if they are using hormone treatment for more than five years. After subcutaneous mastectomy, monitoring of trans men with mammography is not considered feasible owing to the minimal residual breast tissue, and therefore self examination is advised, although there is no evidence for effectiveness. The absolute risk of breast cancer in transgender people is still low in this study, and, more importantly, is not increased compared with cisgender women. We believe therefore that awareness in both doctors and transgender people is of more importance than the start of screening at a younger age or intensifying available screening, even though the median age at diagnosis in the current study was lower than in cisgender women. Besides, discontinuation of hormone treatment in older transgender people can be considered, which might from then decrease the risk of breast cancer. Trans women and trans men who have

| Table 1 | Baseline characteristics of study cohort. Values are medians (interquartile ranges) unless stated otherwise |
|-----------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Characteristics | Overall (n=3489) | Trans women (n=2260) | Trans men (n=1229) |
| Age (years) | 47 (31-57) | 51 (38-60) | 39 (26-51) |
| Age at start of hormone treatment (years) | 28 (21-38) | 31 (23-41) | 23 (19-31) |
| % (No) white | 96.5* (2509) | 96.7* (1579) | 96.3* (930) |
| % (No) ever smokers* | 38.9 (1376) | 39.1 (884) | 38.4 (472) |
| BMI§ | 22.9 (20.5-26.2) | 22.7 (20.5-25.6) | 23.2 (20.7-27.3) |
| % (No) gonadectomy | 68.9 (1556) | 68.5 (842) | 68.5 (842) |
| Oestradiol levels (pmol/L) | - | 217.4 (129-335) | 125** (78-176) |
| Testosterone levels (nmol/L) | - | 1.3 (0.8-1.3) | 23.3 (15.9-35.2) |
| Person time (years) | 12 (4-22) | 13 (5-23) | 8 (3-20) |
| Total person time (years) | 48874 | 33991 | 14883 |

Data available for *2599 people, †1633 people, ‡966 people, §2201 people, ¶1521 people, ††1334 people, **919 people, ‡‡924 people of cohort.

| Table 2 | Standardised incidence ratios of 18 cases of breast cancer (15 invasive and three non-invasive) in 17 trans women and four cases of invasive breast cancer in four trans men |
|-----------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Variables | Observed cases | Expected cases | Standardised incidence ratio (95% CI) | Expected cases | Standardised incidence ratio (95% CI) |
| | | Reference: incidence ratio in cisgender men | | Reference: incidence ratio in cisgender women |
| Trans women (n=2260) | | | | |
| Invasive | 15 | 0.32 | 46.7 (27.2 to 75.4) | 59.95 | 0.3 (0.2 to 0.6) |
| Age (years): | | | | |
| <30 | 0 | 0.00 | - | 0.14 | - |
| 30-50 | 9 | 0.01 | 659.4 (321.6 to 1210.0) | 9.16 | 1.0 (0.5 to 1.8) |
| >50 | 6 | 0.3 | 195.7 (9.7 to 40.6) | 50.65 | 0.1 (0.1 to 0.3) |
| Non-invasive | 3 | 0.03 | 96.1 (24.5 to 261.6) | 12.10 | 0.3 (0.1 to 0.7) |
| Age (years): | | | | |
| <30 | 0 | 0.00 | - | 0.01 | - |
| 30-50 | 1 | 0.00 | 5288.0 (264.6 to 26080.0) | 1.25 | 0.8 (0.0 to 4.0) |
| >50 | 2 | 0.03 | 64.5 (10.8 to 213.0) | 10.83 | 0.2 (0.0 to 0.6) |
| Trans men (n=1229) | | | | |
| Invasive | 4 | 0.07 | 58.9 (18.7 to 142.2) | 18.54 | 0.2 (0.1 to 0.5) |
| Age (years): | | | | |
| <30 | 0 | 0.00 | - | 0.14 | - |
| 30-50 | 2 | 0.01 | 282.3 (47.3 to 932.5) | 4.78 | 0.4 (0.1 to 1.4) |
| >50 | 2 | 0.06 | 32.9 (5.5 to 108.8) | 13.62 | 0.2 (0.0 to 0.5) |
| Non-invasive | 0 | 0.01 | - | 3.35 | - |
not had a mastectomy are advised to undergo the same intensified breast surveillance as their close female relatives if the risk of breast cancer is increased because of a familial predisposition. It is important to remember that transgender people who changed their legal sex might not be automatically invited for population-based screenings, including breast cancer screening.

Strengths and limitations of this study
This study provides novel insights into the risk of breast cancer in transgender people. The reported risk in the current study is higher than estimates from previous studies, possibly related to cohort size and data quality, including the use of a national pathology database. Furthermore, this study included people with a wide range of ages. This study does, however, have some limitations. Owing to the retrospective design of the study, information about hormone use, family history, genetic mutations, benign breast lesions and breast density, tobacco and alcohol use, and body mass index is missing or incomplete. Although these risk factors for breast cancer should not be underestimated, the most important difference between transgender people and cisgender men and women is the use of hormone treatment. It would be interesting to study these risk factors in more detail, to investigate whether certain factors determine the observed increased risk in trans women. The study participants with breast cancer did not necessarily undergo treatment in our centre, and thus detailed data about type and outcome of the treatment are lacking in most of the cases. Although this would be interesting to study in more detail, it was not the purpose of this study. It would be worthwhile for future studies to investigate whether treatment outcomes of breast cancer in trans women are comparable to those of cisgender women.

Conclusions
This large nationwide cohort study in the Netherlands showed an increased risk of breast cancer in trans women compared with cisgender men. The risk in trans women is still lower than in Dutch cisgender women and resembles a more female type of breast cancer and hormone receptor status. In trans men, a lower risk compared with Dutch cisgender women was observed. Based on this study, we conclude that the absolute overall risk of breast cancer in transgender people remains low and therefore it seems sufficient for transgender people using hormone treatment to follow screening guidelines as for cisgender people. As the risk of breast cancer in trans women increased during a relatively short duration of hormone treatment, it would be worthwhile for future studies to investigate in more detail the cause of breast cancer in transgender people receiving hormone treatment.

AUTHOR AFFILIATIONS
1Centre of Expertise on Gender Dysphoria, Amsterdam UMC, VU University Medical Centre, Amsterdam, Netherlands
2Department of Endocrinology, Amsterdam UMC, VU University Medical Centre, Amsterdam, Netherlands
3Department of Clinical Genetics, Amsterdam UMC, VU University Medical Centre, Amsterdam, Netherlands
4Department of Clinical Genetics, Netherlands Cancer Institute, Amsterdam, Netherlands
5Department of Pathology, Amsterdam UMC, VU University Medical Centre, Amsterdam, Netherlands
6Department of Oncology, Amsterdam UMC, VU University Medical Centre, Amsterdam, Netherlands

Contributors: CdB, CW, NN, and MdH designed the study. CdB, CW, NN, KvE, EB, and MdH collected the data. CdB, CW, and NN analysed the data. CdB, CW, NN, KvE, MA, KD, EB, IK, and MdH interpreted the data. CdB drafted the manuscript. CdB, CW, NN, KvE, MA, KD, EB, IK, and MdH revised the manuscript and approved the final version. CdB and MdH are the guarantors. This manuscript is an honest, accurate, and transparent account of the study being reported and no important aspects of the study have been omitted. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding: None.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/col1_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: This study was reviewed by the ethical review board of the VU University Medical Centre Amsterdam. It was determined that the Medical Research Involving Human Subjects Act (WMO) does not apply to this study, and necessity for informed consent was waived. All data were processed anonymously.

Data sharing: Statistics Netherlands prohibit data sharing at an individual level to guarantee the anonymity of the people in its databases.

Transparency: The lead authors (CdB and MdH) affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.


